3D Printed Drugs Market to Reach US$ 2,064.8 Million by 2027 Globally | CAGR: 15.2% | UnivDatos Market Insights

The proliferating prevalence of chronic disease coupled with the surging number of patients with dysphagia across the globe is leading to the growing demand for instantaneous soluble drugs therefore the market of 3D printed is witnessing an uptick. In a report, it was found that the prevalence of dysphagia in the general population of 29 years to 32 years is around 16-23% which is increasing to 27% in those over 76 years of age. Also, a surge in the geriatric population is demanding soluble and personalized drugs. Many older people will have swallowing problems. The prevalence of dysphagia increases with the degree of frailty present and the degree of dependence irrespective of ethnicity. As per the United Nations, there were 703 million persons aged 65 years or over in the world in 2019 and the number of older persons is projected to double to 1.5 billion in 2050. Also, as per the Brazilian Journal of Otorhinolaryngology, approximately 36% of the total population and 65 million people were got affected by dysphagia in 2017and the count is increasing at a steady growth. Furthermore, technological advancements in healthcare owing to the rapidly increasing demand for medicines coupled with the government's emphasis and investments in the 3D printing industry is also contributing to the growth of the market.

Request Sample Copy of this Report @  https://univdatos.com/report/global-3d-printed-drugs-market-current-analysis-and-forecast-2020-2027

COVID-19 Impact

The COVID 19 pandemic has busted out as the demand for medicines, medical equipment, and devices therefore, the adoption of 3D printing has witnessed an uptick. 3D printing is a faster manufacturing technique because of its digital manufacturing capabilities. The companies in the additive manufacturing industry have launched several printers to boost the production of medicines and other required products. During the COVID pandemic, HP deployed "D300e Bioprinter" to researchers to aid in the development of a vaccine and drugs to fight COVID-19 in the U.S. and Europe. Moreover, the drug shortage during the COVID pandemic has gain pharma manufacturers' interest in the quick delivery of medicines. As per the U.S National Library of Medicine National Institute of Health, Medication shortages in 2020 have reached 87% that of the shortages reported in 2019 in half of the time. When considering the effect of the second wave of COVID-19 cases medication shortages will likely continue to escalate.

Ask for Price & Discounts @  https://univdatos.com/report/global-3d-printed-drugs-market-current-analysis-and-forecast-2020-2027

Global 3D Printed Drugs Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

By Technology, the market is primarily bifurcated into

The inkjet printing segment dominated the technology segment of the 3D printed drugs market in 2019 and will grow at 16.63% CAGR to reach US$ 954.1 million by the year 2027.

By Application, the market is primarily segmented into

Amongst applications, the neurology segment accounted for the largest share and is expected to grow at 16.25% CAGR during the forecast period 2021-2027. In 2019, the neurology 3D printed drugs segment accounted for a revenue share of almost 35.1%.

By Drug Form, the market is primarily segmented into

Amongst drug form, tablet form accounted for the largest share and is expected to grow at 16.3% CAGR during the forecast period 2021-2027. In 2019, the tablet drugs segment accounted for a revenue share of almost 29.8%.

By Drug, the market is primarily segmented into

Amongst drugs, Spritam being the FDA-approved first 3D printed drug grabbed the largest share and accounted for 65.2% in 2019. However, other drugs are expected to grow at the highest CAGR during the forecast period.

By End-Users, the market is primarily segmented into

In 2019, the research laboratories segment dominated the global 3D Printed Drugs market with nearly 51.7% of the market share and it is anticipated by 2027, the segment will garner US$ 1,078.2 million of the market.

3D Printed Drugs Market Geographical Segmentation Includes:

Based on the estimation, the North America region dominated the 3D Printed Drugs market with almost US$ 306.8 million revenue in 2019. At the same time, the Asia-Pacific region is expected to grow remarkably with a CAGR of 19.8% over the forecast period owing to the surging government's emphasis on 3D printing in the healthcare industry.

Ask for Report Customization @ https://univdatos.com/report/global-3d-printed-drugs-market-current-analysis-and-forecast-2020-2027

The major players targeting the market includes

Competitive Landscape

The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the 3D printed drugs market. The leading players have been analyzed by using research methodologies for getting insight views on global competition.

Key questions resolved through this analytical market research report include:

We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs.

For more informative information, please visit us @  https://univdatos.com/report/global-3d-printed-drugs-market-current-analysis-and-forecast-2020-2027

Contact:
UnivDatos Market Insights Pvt. Ltd.
4th & 5th Floor,
C-80B, Sector 8, Noida,
Pin code- 201301, UP, India
Ph: +91-7838604911
Email: [email protected]

Logo: https://mma.prnewswire.com/media/1225049/UnivDatos_Logo.jpg